Larson Financial Group’s Anbio Biotechnology NNNN Stock Holding History

Larson Financial Group’s Portfolio NNNN Stock Details NNNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69	Buy	+5	New	+$125	﹤0.01%	3666

Other funds holding NNNN

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFS

Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return

Larson Financial Group's NNNN Position: Q2 2026 in Review

Larson Financial Group opened a new position in Anbio Biotechnology (NNNN) in Q2 2026: 5 shares worth $69. The stake represents ﹤0.01% of the portfolio and ranks #3666 among its holdings.

12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

Larson Financial Group held 5 shares of Anbio Biotechnology worth $69 as of Q2 2026.
Anbio Biotechnology was a new Larson Financial Group position in Q2 2026.
Anbio Biotechnology made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3666 holding.
12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.